Last reviewed · How we verify
AND017 multiple dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AND017 multiple dose (AND017 multiple dose) — Kind Pharmaceuticals LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AND017 multiple dose TARGET | AND017 multiple dose | Kind Pharmaceuticals LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AND017 multiple dose CI watch — RSS
- AND017 multiple dose CI watch — Atom
- AND017 multiple dose CI watch — JSON
- AND017 multiple dose alone — RSS
Cite this brief
Drug Landscape (2026). AND017 multiple dose — Competitive Intelligence Brief. https://druglandscape.com/ci/and017-multiple-dose. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab